Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis

Fig. 5

Forest plot and pooled HR and 95 % CI for subgroup PFS: anti-angiogenesis therapy versus non-anti-angiogenesis therapy. HR hazard ratios, CI confidence intervals, PFS progression-free survival. (a: PFS of subgroups of angiogenesis inhibitors alone threapy; b: PFS of subgroups of angiogenesis inhibitors combined with chemotherapy threapy; c: PFS of subgroups of the first line threapy; d: PFS of subgroups of the second line threapy; e: PFS of subgroups of anti-VEGF threapy; f: PFS of subgroups of anti-VEGFR and multiple receptor inhibitors threapy)

Back to article page